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Summary.-The specificity of the tube LAI in breast cancer was examined in a
study with coded samples of PBL. In addition, 64 patients with breast cancer had
their LAI reactivity monitored and correlated with their clinical status for up to 3
years after mastectomy. When patients were assayed by tube LAI, 83, 72, and 29%o
with Stage I, and II and III breast cancer respectively were positive. In Stage IV
breast cancer, 88% of those with local recurrence and 15% of those with disseminated
cancer were positive. By contrast, 3o% of control subjects were LAI+. A select group
of patients admitted to hospital with suspicious breast lumps that histopathologi-
cally proved to be benign breast disease (BBD) had a higher incidence of LAI+ (12%),
whereas of outpatients with BBD only 2% were LAI+. Most breast cancer patients'
LAI reactivity became negative 2-4 months after mastectomy, even when some
harboured micrometastases. LAI reactivity remained absent in those patients who
remained clinically "cancer-free". In the follow-up patients, LAI activity returned
about 4 months before local recurrence. LAI reactivity was observed in 7/8 patients
in the coded study and 14/15 patients in the follow-up study preceding and/or at the
time of local recurrence. A few patients (15%o,) progressed to widespread cancer with-
out preceding positive LAI activity. The results suggest that tumour-specific im-
munity rapidly fades after surgery and may play no role in the rejection of micro-
metastases by 6 months after surgery. In addition, the present study has shown that
the human host manifests tumour-specific immunity when the cancer is small, and
suggests that the early detection of human cancer would depend upon reliable
methods to measure the tumour-specific immune response.
DURING the past 4 years our laboratory
has assessed specific immunity to human
breast cancer by the in vitro assay of
tube leucocyte adherence inhibition (tube
LAI) (Grosser & Thomson, 1975, 1976;
Marti & Thomson, 1976; Grosser et al.,
1976; Marti et al., 1976; Flores et al.,
1977; Thomson et al., 1976). This assay
was modified from that of Holan et al.
(1974) and is based on the discovery of
the leucocyte adherence inhibition (LAI)
phenomenon by Halliday & Miller (1972).
Many other investigators who have used
LAI to study the host's immune response
to animal and human tumours have re-
ported that the assay reliably tmeasures
the tumour-specific immune response of
the host (Holt et al., 1975; Leveson
et al., 1977; Maluish & Halliday, 1974;
Powell et al., 1975; Fujisawa et al., 1977;
Rutherford et al., 1977). In contrast,
Hellstrom et al. (1977), who used the tube
LAI assay in malignant melanoma, found
that although the response was tumour-
specific, there was too much non-specificity
to be of clinical value. Also, stage of
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disease, amnount of clinically detectable
tumour and clinical status did not influ-
ence their LAI results. Similarly, Hell-
strom et al. (1976), in an experimental
animal-tumour model, found specific LAT
reactivity, but great variation between
individual tests. Likewise, Armitstead &
Gowland (1975) also reported lack of
specificity of an LAI assayT in colon
cancer, where 590 of colonic-cancer
patients and 3000 of control subjects
showed LAI to a perchloric-acid extract
of colonic cancer.
Our studies indicated that in cancer
patients, tumour-specific immunity was
generally present with small tumour
burdens, and was more often absent from
widespread metastasis (Grosser & Thom-
son, 1975, 1976; Marti & Thomson, 1976;
Marti et al., 1976; Thomson et al.,
1976). In patients with limited cancer,
removal of the primary tumour was
followed within 3-4 months by a
loss of LAI reactivity in patienits con-
sidered to be clinically "cancer-free"
(Marti & Thomson, 1976; Flores et al.,
1977). Leucocytes of patients with ad-
vanced cancer were not LAI+ because
free breast-tumour-specific antigen (TSA)
in the systemic circulation coated the
cell surface of the leucocyte and abro-
gated the response to antigen present in
the in vitro assay (Grosser & Thomson,
1976; Lopez & Thomson, 1977). More-
over, the breast TSA shed from the
tumour-cell surface was present in
serum and co-isolated with the high-
density lipoproteins and HLA antigens
(Lopez & Thomson, 1977). In addition,
some of the excess TSA in the systemic
circulation was degraded and cleared
by glomerular filtration into the urine
(Lopez & Thomson, 1977).
In the present study, the relationship of
tumour immunity to clinical behaviour of
the cancer up to 3 years after mastectomy
was examined in 64 patients, in an
attempt to increase the understanding
of the biological events of tumour growth
and antitumour immunity that follow
excision of the primary cancer. The
present study in breast cancer and coiitrol
subjects was also undertaken to deter-
mine the specificity of the tube LAI assay
when leucocyte samples were coded.
MATERIALS AND METHODS
Subjects. The TNM classificationi by the
International Union Against Cancer for
clinicopathological staging of breast cancer
was used. Patients admitted to hospital with
breast nmasses, patients with a mastectomy
admitted for investigation or treatment of
local recurrence of breast cancer or dis-
seminated disease, as well as various control
groups, were tested for tube LAI before
surgery or any other treatment. A total of
451 patients were assayed, of whom 139
had new breast lesions, benign or malignant.
A further group of 41 outpatients suspected
of breast pathology, who were referred for
mammography, were assayed for tube LAI.
Control subjects who were tested were
divided into 2 groups: 92 patients with
malignant tumours other than breast cancer,
and 138 patients w%ith benign surgical
disorders.
In the second part of the study, 64 patients
who underwent mastectomy were monitored
by the tube LAI every 3-6 mouths, with
some patients being monitored for over 3
years. The patients studied were those who
were LAI+ before surgery and wNho returned
for LAI blood tests. The pathological stages
of these patients at surgery was 27 Stage 1,
31 Stage II and 6 Stage 111. Most of the
LAI values were correlated with the cliinical
results at the end of the first, second and
third year of the study. However, when a
patient was LAI+ this was reported to the
attending surgeon and the LAl result was
then correlated with the clinical status of
the patient. In this study, a single NAI value
of > 30 6 months or more after surgery
resulted in the patient being recorded as a
positive responder. The patients were ex-
amined by their private physician or at the
Oncology Clinic of the Montreal General
Hospital every 3 months.
Tumour extracts.-Phosphate-buffered sa-
line (PBS, pH 7 3) extracts of malignant
melanoma and cancer of the breast, colon,
stomach and pancreas were prepared as
described by Grosser & Thomson (1975).
The protein concentrations were determined
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by the method of Lowry et al. (1951) with
bovine albumin as a standard, and the
extracts ofthe specific cancer (breast) and the
controls (melanoma) wN-ere titrated against
peripheral blood leucocytes (PBL) from
reactive breast-cancer patients and control
sub)jects as previously described (Marti &
Tlhomson, 1976; Flores et al., 1977). The
optimal protein concentration was about
100 + 10 Htg per tube. In the coded study
conducted over a period of 1 year, the breast-
cancer extract was made from portions of the
same breast cancer. During the 3-year
follow-up study, a variety of cancer extracts,
specific and non-specific, wrere prepared and
used for the study. Most extracts prepared
from breast cancers and malignant melanoma
have had activity wAhen used in the tube
LAT assay, though some extracts have seemed
better than others in terms of consistent
non-specific inhibition of adherence of leuco-
cytes from control subjects. There was no
discernible difference in the preparations
selected for use in this study. Except for the
study on the tumour specificity of the LAI
response, routine testing was performed
M-ith the extracts of breast cancer and malig-
nint melanoma.
T'he antigen-induced tube leucocyte-adherence-
in,hibition assay (tube LAI assay). The tube
LAI assay M-as performed as described in
detail by Grosser & Thomson (1975). PBL
from breast-cancer patients and control
subjects were collected and prepared as
previously described (Grosser & Thomson,
1975). The cells were then plated in separate
glass test tubes with the specific and control
antigens, and incubated in a horizontal
position at 37°C in a 5%0 CO2 humidified
atmosphere. After 2 h the tubes were placed
vertically, and a sample of the non-adherent
cells were counted on a haemocytometer with
a Leitz Dialux microscope wN-ith phase
contrast.
The results wAere expressed as a nonadher-
ence index (NAT)
Non-adherent Non-adherent
cells in cells in
presence of -presence of
specific non-specific
NAl antigen antigen _x 100 Non-adherent cells in presence
of non-specific antigen
An NAI value > 30 was considered
positive, on the basis that more than 95°,
of the control population wras negative, and
more than 80%O of patients wA-ith limited
cancer were positive to the sensitizing antigen
(Marti & Thomson, 1976; Flores et atl., 1977).
PBL samples wiere coded by laboratory
personnel not involved in the clinical studies
of LAI. The tests were performed before
surgery, and all patients with breast lumps
were tested together with one or more
control subjects. The LAI results for each
patient were known on the day of the LAI
test, and wN-ere correlated with the patho-
logical results wAhich became available 7-10
days later. The tube LAI assay was per-
formed independently by M. Lopez and R.
O'Connor and the results of the 2 investi-
gators were pooled.
RESULTS
LAI response directed to an oryan-type-
specific antigen
Routinely, a pair of extracts was
appropriately titrated (Marti & Thomson,
1976) for use in the tube LAI assay. The
pairs of cancer extracts consisted of
breast and melanoma and, more recently,
colon and lung, pancreas and lung, and
stomach and lung. The extract of malig-
nant melanoma was the non-specific
antigen in the coded study of LAI
reactivity to breast cancer. Nevertheless,
the extract ofmalignant melanoma showed
specific antigen activity when incubated
with leucocytes from patients with malig-
nant melanoma. By studying the tumour-
specific immune response to one pair of
extracts, it has proved possible to main-
tain the experimental error (false positives)
to about 3°, (O'Connor et al. in press)
to one antigen of the pair. The different
cancer extracts can be freely interchanged;
if, however, the number of extracts to
which a patient is tested is increased, the
experimental error may be expected to
rise as a result of more assays being done.
In addition, the percentage of patients
positive to a single antigen of a panel of
antigens will also rise. Table I shows the
results when leucocytes from patients
with limited cancer and control subjectsLAI REACTIVITY IN BREAST CANCER
TABLE I.-LAI reactivity to a panel of cancer extracts of
different histological origins*
Diagnosis of
leucocyte
donor
1. Breast
cancer
2. Malignant
melanoma
3. Colon cancer
4. Pancreatic
cancer
5. Lung cancer
6. Control
subject
7. Control
subject
8. Control
subject
9. Control
subject
10. Control
subject
Mean No. ±s.d. of non-adherent cells to a panel of cancer extracts of
Breast Melanoma Colon Pancreas Stomach Lung
79±11 58-5 59±9 55±1 50+2 48±5
43±2
28±3
30±3
40±9
23±4
51±2
41-46
67±5 48+6 41±3 49±5 50±5
26±4 39±3 28±2 30±2 28±1
27±5 29±7 49±8 26±3 23±4
34+5
28±1
38±7 46±9 44±6 78± 13
30±4 30±3 26±4 25±2
57±14 49±8 54±11 50±5 52±2
41±3
50±12 54±1
62±11 49±7
43± 13 45±5 43±6 44±4
67± 14 - 59±9
53-4-6 51±3 64±11 59±15
* NAI is calculated as ABB x 100, where A=specific antigen and B=non-specific antigen. Hence, LAI
reactivity to each antigen can be calculated 5 ways with the other 5 antigens.
were incubated with 6 different cancer
extracts. The highest number of donor
leucocytes were non-adherent when in-
cubated with an extract of cancer identi-
cal to the tumour of the donor. More-
over, in the patients with cancer an
NAI value > 30 was observed when the
specific antigen was paired with any of
the non-specific antigens. Each patient
with cancer had, therefore, a total of 5
positive tests to the sensitizing cancer
antigen.
If the various antigens are freely
interchanged to calculate the NAI, the
results show 6 false-positive responses
(Table I). NAI values between 30 and 35
are given to breast-cancer antigen by
the Breast/ILung combination, in Patient
No. 4 with pancreatic cancer; to pancreas-
cancer antigen by the Pancreas/Melanoma
combination in Patient No. 5 with lung
cancer; to colon-cancer antigen and pan-
creas-cancer antigen by the combination
of Colon/Breast, Pancreas/Breast, respec-
tively in Control Subject No. 6; to colon-
cancer antigen by the Colon/Breast com-
bination in Control Subject No. 9; to
stomach-cancer antigen by the com-
bination of Stomach/Melanoma in Control
Subject No. 10. By our method of pairing
the tumour extracts to calculate the
NAI, if each patient was tested with 6
extracts, this resulted in a total of 30
permutations of tests for each patient,
and the 10 patients had 262 tests. The 6
false-positive results represented, there-
fore, an experimental error of 2a1%.
Although the experimental error was low,
3/6 control subjects had an LAI+ response
to one of the antigens and 2/4 patients
with cancer reacted falsely to an unre-
lated extract of cancer. It was of interest
that the false positives occurred not
within the standard pairs but between the
pairs, in part, perhaps because the extracts
of each of the pairs had not been as
carefully titrated against the other pairs.
In addition, Table II shows that 92
patients with a variety of limited cancers
were tested against the pair of extracts of
breast cancer and melanoma with 3
positive responses (3%) to the breast-
cancer extract. In spite of the false-
positives recorded in Table I, the results
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TABLE IT. Coded study of tube LAI assay in breast-cancer patients and control subjects*
Diagnosis of patients studied
Breast cancer
Stage I
Stage II
Stage III
Stage IV
Local recurrence
Disseminate(d
Benign breast (lisease
In-hospital patients
Outpatients
Unrelated malignancies
Non-malignant surgical (liseases
No.
testedl
24
25
14
8
33
76
41
92
138
LAI+ patients
No. (%)
20 (83)t
18 (72)t
4 (29)
7 (88)
5 (15)$
9 (12)
1 (2)
3 (3)
4 (3)
* Patients with Stage I, II, III breast cancer, with unrelated malignancies, with non-malignant surgical
(liseases, an(I with benign breast disease (in-hospital) were tested before surgery. Stage IV patients were
teste(l before surgery, irradiation or chemotherapy.
t Significantly different from control subjects (P < 0-001).
+ Significantly different from Stage I and II breast cancer patients (P' < 0.01).
indicate that the LAI response is directed
to an organ-specific antigen.
Another feature of the tube LAI assay
was that the PBL from different donors
exhibited variable non-adherence (Table
I) which also varied each day. To detect
a tumour-specific immune response it
was essential, therefore, to compare the
difference in non-adherence when the
PBL were incubated with specific and
non-specific extracts of cancer.
A coded study of tube LAI
A total of 451 patients were tested
independently by 2 experimenters
(Table II). The LAI results of the 2
experimenters were similar for both con-
trol subjects and patients with breast
cancer, so it has been possible to pool the
results (summarized in Table II). In
addition, many of the same patients with
breast cancer were tested by both investi-
gators either on the same or separate
days with similar results. The similar
results by both investigators when testing
the same patient or when their overall
results xvere compared indicated that the
tube LAI assay was reproducible.
Of the group of patients tested, 139
were admitted to hospital with a breast
mass which was thought to be malignant
by the attending surgeon. The pathology
of the excised breast tissue showed that
24, 25 and 14 had Stage I, II and III
breast cancer, respectively, though 76
proved to have benign breast lesions.
Before surgery, 83% of Stage I, 72% of
Stage II, and 29% of Stage III patients
were LAI+ (Table II). By contrast, 12% of
the patients with benign breast lesions
had a positive LAI test before surgery.
A positive LAI response was exhibited
by 4 patients who had no palpable breast
mass, but were admitted to hospital
because of mammographic suspicion of
breast cancer. At surgery they were
found to have breast cancer. In addition
one patient included in Stage I who had
lobular in-situ breast cancer was LAI+.
Patients with Stage IV breast cancer
were divided by clinical evaluation into
patients with local recurrence and wide-
spread metastasis. Of those with local
recurrence, tested before the recurrence
was proven by biopsy, 7/8 (88%) were
LAI+, whereas only 5/33 (15%) patients
with widespread metastasis were LAI+
(Table II).
The rate of LAI+ for the group of
patients with breast masses who proved
to have benign breast disease (BBD) was
higher than in the other control subjects.
To determine whether all BBD patients
showed a similar high degree of LAILAI REACTIVITY IN BREAST CANCER
reactivity to the breast-cancer extract, a
second group of 41 patients attending a
mammography outpatient clinic were test-
ed. The clinical and mammographic diag-
nosis in these 41 patients was later
correlated with the LAI results, and all
the patients had BBD. Of these 41, one
(2%/) was LAI+ (Table II), but, when this
patient was assayed on 2 subsequent
occasions, she was LAI-, and the response
to a panel of breast cancer antigens was
also negative (O'Connor et al., in press).
In the control groups, 92 patients who
had malignant lesions other than of the
breast were assayved (Table II). This group
comprised a variety of gastrointestinal
cancers, including pancreas, colon, stom-
ach and hepatomas, as well as squamous-
cell carcinomas of the floor of the mouth,
larynx and bronchi, melanoma, ovarian
cancers, sarcomas and lymphomas. All
patients were tested before surgery or
treatment. Three patients in this group
were LAI+ (Table II). One was a woman
originally admitted to hospital for a breast
lesion that was histologically benign on
biopsy, and while in hospital was found
to have ovarian cancer which had meta-
stasized to omentum. She was included as
a false-positive in the unrelated-malig-
nancy group. The second false-positive
was a man with lung cancer who had a
positive response to breast-cancer extract
because of an abnormally low cell count
with the melanoma antigen, the non-
specific antigen. However, when leuco-
cytes of this patient were tested against
extracts of lung cancer and breast cancer,
an LAI+response to lung cancer and not to
breast cancer was observed. The third
LAI+ patient had a negative response
Nrhen retested twice more, suggesting
that the initial result was an experimental
error.
Patients in the second group of control
subjects, with a variety of benign surgical
conditions, were tested before surgery and
4/138 (3 women and 1 man) were LAI+.
No relationship was found with either
family history of breast cancer or symp-
toms of breast disease. Moreover, 3/4
positive responders, when retested on 2
more occasions, were negative, suggesting
that the initial LAI+ was an experimental
error (O'Connor et al., in press). The com-
bined false-positive rate in the 2 groups
of control subjects was 30o. Hence, the
NAI values are less than 30 in more than
95% of instances, when leucocytes of
control subjects are tested against breast
cancer as the specific antigen. In addition,
about 300 of control subjects without
malignant melanoma had NAI values less
than 30 and would be considered false-
TABLE III.--Mean number of non-adherent leucocytes from control subjects and patients
With limited and metastatic breast cancer to extracts of breast and melanoma cancer
Groups II
1. Control subjects
2. Patients with
earlv breast
cancer
3. P"atients vvith
metastatic
breast canicer
Non-adherent cells to
breast cancei
Coeff. of
Mleaii±s.(l.* variationt +
:37 - 12 32 1 vs:3
<0-05
60 t+10 16 2 vsI
<0-001
50 27 54 3 .s 2
<0(05
Non-adlherent cells to melanoma
Coeff. of
Mlean{s.(l.* variationt P+
37 +12 32 lvs3
37+8
,>4I 28
<0 02
21 2vs I
N.8.
55 5 3 vs 2
<0 02
NAT§
0
59
-3
* Th-ie mean of non-adherent samples of cells from the 30 test tubes in the 10 patients.
ts.d./Mean 0/O.
+ Stud(lent's t test between groups.
§ Calculated from the means.
Ti\i1 patients in each gronip.
665666 M. LOPEZ, R. O'CONNOR, J. K. MACFARLANE AND D. M. P. THOMSON
positive to the non-specific antigen of
malignant melanoma.
Mean antigen-induced non-adherence of
leucocytes from breast-cancer patients
Breast cancer patients and control
subjects tested during a period of about 3
months with the same specific and non-
specific tumour extracts were allocated to
3 groups (Table III). Group 1 was control
subjects with benign surgical conditions.
Group 2 was LAI+ patients with localized
breast cancer. Group 3 was patients with
metastatic breast cancer and LAI- (Table
III). In this analysis, the breast-cancer
patients were chosen consecutively until
each group had 1O patients. The group of
control subjects consisted of those who
were tested on the same day as the selected
breast-cancer patients.
Table III shows the mean leucocyte
non-adherence ofthe 3 groups. Leucocytes
from Group 1 were equally non-adherent,
when incubated with the 2 cancer
extracts. PBL from Group 2 incubated
with the non-specific cancer extract, had a
mean non-adherence similar to Group 1.
By contrast, the leucocytes from Group
2 incubated with an extract of breast
cancer, the sensitizing cancer, had a
mean non-adherence significantly higher
(P < 0-001).
Leucocytes from Group 3 showed a
mean non-adherence significantly higher
than Group 1, when incubated with the
extracts of breast cancer and melanoma
(Table III). The mean non-adherence of
leucocytes from Group 3 patients was
lower, however, than in Group 2 when
incubated with the extract of breast
cancer. When more groups of patients
were similarly examined, the results wTere
the same, except that the mean non-
adherence of leucocytes from Group 3
patients to the specific and non-specific
antigens were almost equal to the mean
non-adherence of leucocytes from Group
2 patients when incubated with the
specific antigen.
Follow-utp of patients after mastectomy by
the tube LAI assay
Included in this study were 64 patients
who were LAI+ before surgery (Table
IV) and in 62 of these the LAI became
negative 2-4 months after surgery. The
patients were divided according to the
month after surgery when the study was
closed (Table IV). To date, 30 patients
(47%0) subsequently had a positive LAI
TABLE IV. Follow-up of 64 mastectomty patients by the tube
LAI: correlation between LAI response and cancer recurrence
LAI+ patieints
. _
Prog.
Loc. rec.* diss.t
4 3
.5 4
2
3 2
14** lItt
LAI- patients
Loc. Diss.
Total (0O/) rec.* Ca.t
1 (14) 0 1
10(50) 1 1
16 (61) 0 0
7 (64) 0 2-T
34 (.53) 1* 4tt
* Patients with local recurrence.
t Patients who progressed to (lissemination.
t Patients with disseminate(d cancer who never ha(d evi(lence of local recurrence.
§ Patient without (locumented local recurrence, btut presented with wNidespread cancer. LAI- throughout.
Patient Nwith Stage I cancer at surgery, presented 1 year after surgery ith a lairge ovarian mass which
piovedl metastatic from breast. LAT- throughouit.
Two patients lost, to follow-up for one year. Both appeare(l for clinical examination show,,ing disseminated
dlisease. LAI- at, the clinical investigation.
** The (lifference between the proportions of patients with recurrent (lisease who were LAT-P an(d LAI-
is highly significant. X2 14 63; P < 0*001).
tt The difference between the proportion.s who progressed to (lissemination between LAI+ andl LAT-
patients is less significant (X2 4-21; P < 0)-05).
Time after
mastectomy
(months)
12-18
18-24
24-36
36 1
Total
No.
teste(l
7
20
26
11
64
Total (0o)
6 (86)
10 (50)
10 (38)
4 (36)
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6 months or more after surgery. Of these,
14 have had histologically proven local
recurrence ofbreast cancer and 11 ofthese
14 have eventually progressed to widely
disseminated breast cancer. The remain-
ing 16 LAI+ patients have been followed
for an average of 4 months, and as yet
have no clinically detectable recurrence.
In the group of 34 (53%) patients who
have remained LAI- 6 months or more
after surgery, 5 (15%) presented with
clinical evidence of local or disseminated
cancer (Table IV). One patient had clini-
cally evident ovarian metastasis 11 months
after surgery and another showed metas-
tatic disease 20 months after surgery, both
having repeatedly LAI- assays throughout
themonitoringperiod. Thethirdandfourth
patients were lost to LAI follow-up for
1 year, after which they presented with
metastatic cancer. No local recurrence
of breast cancer was demonstrated in
these 4 patients with a negative LAI. The
1 LAI- patient with local recurrence was
tested at 5 months, on the day before
biopsy was carried out on the local
recurrence. Manyofthe remaining patients
in this LAI- group presumably have no
residual cancer, though the possibility that
some harbour undetectable micrometa-
stasis cannot be excluded.
Table V shows the results when the
64 follow-up breast-cancer patients were
grouped according to the stage of cancer
at surgery, their LAI response 6 months
or more after mastectomy and the re-
currence of cancer. The percentage of
patients who became LAI+ 6 months or
more after surgery was highest in Stage
III cancer and lowest in Stage I (Table
V). Likewise, the development of proven
local recurrence in the LAI+ patients was
highest in Stage III and lowest in Stage
I (Table V). The highest percentage of
LAI+ patients with no evidence of re-
current cancer was found in the patients
with Stage I breast cancer. Only 20% of
Stage I LAI+ patients have to date
developed local recurrence, whereas 75%
of LAI+ Stage III have done so.
In the patients who have developed
recurrences, the LAI response became
positive about 4 months (range 1-7)
before the local recurrence was detected.
In addition, the LAI+ patients who
developed local recurrence had a negative
LAI value about 4 months (range 1-13)
before the positive test. In the group of
LAI+ patients with local recurrence, LAI
reactivity was recorded about 9 months
(range 4-13) before the appearance of
distant metastasis.
Patterns of LAI reactivity in follow-up
mastectomy patients
Figs. 1-5 show the 5 patterns of LAI
reactivity observed when patienta were
monitored before and after mastectomy.
Fig. 1 illustrates patients progressing
rapidly to the metastatic stage of cancer.
Two patients were LAI+ at 6 or 7 months,
and shortly after presented with clinical
evidence of recurrent cancer, though as
the tumour grew LAI reactivity was lost
and clinical evidence of disseminated
cancer followed. The third patient was
LAI+ before surgery but later showed no
LAI reactivity and presented within a
year with evidence of disseminated breast
TABLE V.-Stage at initial surgery, LAI response 6 months or more after
mastectomy and cancer recurrence in 64follow-up breast-cancer patients
LAI+ patients
Stage of No. I
cancer tested Total (%) Loc. rec.* Prog. diss.t
I 27 10 (37) 2 1
II 31 16 (52) 9 7
III 6 4 (67) 3 3
LAI- patients
>~~
Total (%)
17 (63)
15 (48)
2 (33)
Loc. rec.* Diss. ca.+
0
1
0
1
3
0
* Patients with local recurrence.
t Patients who progressed to dissemination.
t Patients with disseminated cancer who never had evidence of local recurrence.
45
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FIG. 1. LAI of leucocytes from 3 patients FIG. 3. LAI becoming positive more than
with local recu1rrence within 6-12 months 6 months after surgery in patients who
of surgery. are clinically "cancer-free".
FIG. 4. LAI becoming positive more than
6 months after surgery in patients who
later presented with local recurrence.
SURGERY MONTHS POST SURGERY
FIG. 2. LAI in 4 patients who are clinically
"cancer-free".
cancer. Fig. 2 illustrates patients who to
date have not developed clinically detec-
table recurrence of breast cancer. In-
variably, these patients become LAI-
2-4 months after surgery and remain
negative. This does not differ from the
pattern of the third patient in Fig. 1,
except that the patients in Fig. 2 have
remained clinically "cancer-free". Figs.
3 and 4 illustrate the third and fourth
patterns. Here, although the patients are
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FIG. 5. LAI becoming positive with local
recurrence and then negative as the ttumour
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LAI- in the 2-4 months after surgery,
they become LAI+ again after 6 months.
Fig. 3 shows 3 LAI+ patients who are
clinically "cancer-free". In Fig. 4 a
similar pattern is seen, except that local
recurrence of breast cancer has now
become evident. Fig. 5 shows the sequence
of events in patients who develop local
recurrence more than 1 year after mastec-
tomy. The LAI+ response before surgery
becomes negative 2-4 months after sur-
gery and remains negative until about
4-5 months before the local recurrence is
detected clinically. The LAI response
remains positive for a variable time, but
the change from LAI+ to LAI- usually
precedes evidence for clinical dissemina-
tion.
DISCUSSION
The validity of the in vitro micro-
cytotoxicity assay for assessing whether
human tumours do indeed express neo-
antigens capable of host recognition has
recently been questioned (Baldwin, 1975;
Herberman & Oldham, 1975). Partly
as a response to the difficulties experienced
with the various methods for measuring
in vitro cytotoxicity of PBL from cancer
patients, attention has been directed
towards developing alternative in vitro
tests of cellular immunity to human
tumours. The phenomenon of tumour-
antigen-induced inhibition of leucocyte
adherence to glass (Halliday & Miller,
1972) appears to be a most promising
in vitro technique. The results of the
present study indicate that the assay
is able to detect a host response to an
organ-specific neoantigen expressed upon
human cancers.
The results of the present study of tube
LAI in breast-cancer patients and control
subjects, in whom the PBL samples were
coded and tested independently by 2
investigators, are similar to previous
results from our laboratory (Grosser &
Thomson, 1973; Flores et al., 1977). A
high percentage of patients with small
tumour burdens or early cancer were
LAI+, 83% in Stage I and 72% in Stage
II, compared with only 15% of patients
with large tumour burdens, Stage IV, with
widespread metastasis. In this and our
previous study (Flores et al., 1977)
patients with Stage III cancer had
decreased reactivity, 29 and 450%, respec-
tively. On the other hand, about 88% of
patients with Stage IV cancer with local
recurrence, compared to 1500 with wide-
spread metastasis, were LAI+. In the
patients with local recurrence, the tumour
burden was apparently not large enough
to release sufficient TSA to abrogate the
LAI response (Grosser & Thomson, 1976;
Lopez & Thomson, 1977). In Stage IV
cancer, the presence of LAI reactivity
suggested a limited tumour load, whereas
absence of a LAI response signified a
large tumour load.
About 300 of control subjects had a
positive LAI to the breast-cancer extract.
Most of the control subjects with a false
LAI+ were shown to be the result of ex-
perimental error. Thus, the experimental
error in the tube LAI assay to a single
antigen ofthe pair ofextracts is about 3 o.
If the number of extracts to which the
patients are tested is increased, the rate of
false positives may rise. With 6 different
cancer antigens and the use of our formula,
there are 30 permutations by which the
NAI can be calculated for the non-
adherent PBL from one subject incubated
with the 6 antigens. An experimental
error rate of 2.5% will lead to more than
5000 of tested control subjects being
apparently positive once in the 30 possible
permutations of the 6 antigens. By con-
trast, PBL from a tumour-bearing patient
with tumour-specific immunity can be
expected to be positive to the sensitizing
antigen in 5/5 possible combinations in
which the sensitizing antigen is the
specific antigen, out of the 30 different
permutations for calculating the NAI, a
result which is markedly different from
the control subjects. Nevertheless, in the
present state of development of the tube
LAI, the use of a panel of cancer extracts
has little applicability as a cancer-screening
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test. Moreover, 17% and 28% of patients
with Stage I and II breast cancer had
negative assays and 12% of patients with
histopathologically proven fibrocystic dis-
ease of the breast were positive. The
results of the present study clearly indi-
cate that the tube LAI assay is not useful
in the diagnosis of early breast cancer.
The tube LAI assay when used to
monitor mastectomy patients also proved
to be of minimal value. The assay did not
indicate whether or not the patient was
free of cancer, since the LAI response of
patients with or without micrometastasis
became negative 2-4 months after mastec-
tomy.
Of the 64 patients monitored, 30 (47%0)
were LAI+ at least once during 6 months
or more after surgery. Fourteen (47%0) of
these patients have, to date, developed
clinically recurrent cancer. Sixteen pa-
tients who remained clinically free of
cancer have had a positive LAI. Assuming
that the assay has a 3% error rate, with
most patients being repeatedly assayed,
about 5/16 could be expected to have a
positive test as a result of experimental
error. Many of the 16 patients, however,
did have a second positive assay which
confirmed the preceding result.
The clinically detectable local recur-
rence of cancer was preceded by an
LAI+ assay an average of 4 months
before, and distant metastasis occurred
about 9 months after an LAI+ response.
Thus LAI activity did not reflect any
evidence of host resistance. Moreover,
with the short lag between an LAI+ and
recurrence, it is doubtful whether the
detection of an LAI+ response could be of
therapeutic benefit.
An LAI- response was recorded in 34
(53%) ofthe monitored patients, ofwhom
5 (15O/,) developed recurrence. Of these 5
one had local recurrence while the other
4 presented with metastatic cancer. Thus
not all patients can be expected to have
an LAI+ response preceding recurrence.
Nevertheless, about 90o% of patients,
7/8 in the coded study and 14/15 in the
follow-up study, were LAI+ before or at
the time of local recurrence, whereas 85%0
of patienits who remained LAI- are
clinically "cancer-free" (P < 0O001).
In spite of the lack of clinical value of
the tube LAI assay for diagnosis, the
results of the present study indicate that
thehost's tumour-specificimmuneresponse
can reliably reveal interesting facets of
the biology of breast cancer. The LAI
activity in patients with a local recur-
rence argues against the concept that
the cancer cells in a metastatic tumour are
selected on the basis of a lack of anti-
genicity and failure to stimulate an
immune response (Haywood & McKhann,
1971; Black et al., 1976; Deichman &
Kluchareva, 1966; Fenyo et al., 1968). In
addition, the metastatic tumour deposits
and primary tumour were equally anti-
genic in the in vitro tube LAI assay.
Thus the metastatic tumour did not
differ appreciably in expression of TSA
from the primary tumour, although slight
quantitative and qualitative differences
of TSA expression in primary and metas-
tatic tumours might not be detected by
the in vitro tube LAI assay.
Moreover, calculation of the mean non-
adherence of leucocytes from groups of
control subjects and patients with limited
and metastatic breast cancer, indicated
that the metastatic tumour was produc-
ing and shedding TSA into the circulation
which coated in vivo LAI-reactive cells
and caused the loss of their property of
glass adherence when incubated in vitro
with either specific or non-specific cancer
extracts. By contrast, in patients with
limited cancer, the circulating mono-
cytes by and large have not yet encoun-
tered TSA, so that they have retained
their glass adherence when incubated
with non-specific antigens.
LAI reactivity to the tumour disap-
peared rapidly (2-4 months) after re-
moval of the principal source of the anti-
genic stimulus, the primary cancer, even
when some patients harboured distant
micrometastases. The disappearance of a
measurable antitumour immune response
in the patients who had micrometastasesLAI REACTIVITY IN BREAST CANCER 671
possibly reflected a quantity of metastatic
cancer that was too small to provide an
adequate antigenic stimulus to the im-
mune system. In Stage I breast cancer,
many patients were LAI+ when the
tumour burden was small or even in
situ, and hence the lack of LAI+ in
patients with micrometastases was not
necessarily the result of an insensitive
assay method. When the distant micro-
metastases grew, LAI of the host's
circulating leucocytes again became
detectable, suggesting that a certain
minimum of tumour was required to
stimulate the immune system. This quan-
tity of tumour needed to trigger the
immune response is not known. Many
local recurrences are 1 cm in size and a
lcm tumour contains 109 cancer cells.
The presence of LAI reactivity some
months before the tumour is detectable
suggests that 105-106 tumour cells may be
required to stimulate the LAI response.
Another possible explanation of the disap-
pearance of antitumour immunity in
patients after surgery who harbour micro-
metastases is that the cancer cells are in
an immunologically privileged location.
The LAI results of the monitored
patients suggests that the antitumour
immunity of the host fades, and that the
tumour-specific immune response ceases to
play an active role in the rejection of
micrometastases by 6 months after sur-
gery. Not until the micrometastases have
increased in cell numbers does the im-
mune system return. Of course, other
aspects of the tumour-specific immune
response, not measured by tube LAI,
could be active, and their failure may
allow the tumour to escape and enter
a rapid growth phase. Assessment of
other aspects of the immune response
to tumours by in vitro assays of micro-
cytotoxicity, cytotoxicity and macro-
phage migration in human tumours have
also detected, however, the waning of
antitumour immunity after surgery (An-
derson et al., 1970; Bull et al., 1973;
Jones & Turnbull, 1974; Reiche et al.,
1976; Elias et al., 1977; Canevari et al.,
1975; O'Toole et al., 1973; Unsgaard &
O'Toole, 1975).
In an animal model, Eccles & Alexander
(1972) showed that the antitumour im-
mune response expressed in the first
month after surgery is critical in deter-
mining whether micrometastases are re-
jected or eventually grow. In human
cancer the extent and duration of the
transient immunosuppression produced
by surgery (Grosser & Thomson, 1975;
Marti & Thomson, 1976) and the vigour
of the antitumour immune response in
the month or soimmediately after surgery,
may prove to be critical factors that
determine the fate of micrometastases.
In aIn animal tumour model, the host's
tumour-specific immune response was
detectable before TSA could be measured
in the circulation (Thomson, 1975). Sero-
logical tests for the detection of tumour
products in human sera, such as carcino-
embryonic antigen (Thomson et al., 1969)
and alkaline phosphatase (Foti et al.,
1977), give the greatest values when the
tumour burden is comparatively large.
The present study suggests that the
human host also expresses tumour-specific
immunity when the tumour burden is
small; thus, the early detection of human
cancer by immunological assays will
depend on the development of reliable
methods to measure the antitumour
immune response.
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